Skip to main content
GNLX logo

Genelux Corporation

GNLXNASDAQHealthcareBiotechnology

$2.42Today:- (-)1Y −56.64%

As of Oct 16, 2026 close

Market cap
$111.50M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.29$8.54
Volume (live)
-
Avg. volume (3M)
264.08K

Genelux (GNLX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Genelux reported total assets of $19.03M and total liabilities of $7.48M. Shareholders' equity was $11.54M, down 56.1% from $26.27M a year earlier. Total debt stood at $1.69M against $14.60M in cash and short-term investments, a net cash position of $12.91M. That puts debt-to-equity at 0.15, compared with 0.07 a year earlier.

Genelux Balance Sheet Analysis

Values in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Genelux Corporation (GNLX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Mar 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Current Assets
Cash and Cash Equivalents5.338.579.429.420.404.5011.350.43
Short-Term Investments9.2622.3313.7713.770.000.000.000.00
Cash & Short-Term Investments14.6030.9023.1923.190.404.5011.350.43
Accounts Receivable0.000.000.00-0.000.000.000.00
Inventory0.000.000.00-0.000.000.000.00
Other Current Assets0.540.651.011.011.501.330.130.13
Total Current Assets15.1331.5524.2024.201.895.8211.480.55
Non-Current Assets
Property, Plant & Equipment (Net)3.753.083.603.601.982.212.452.65
Other Non-Current Assets0.140.090.090.091.660.090.080.08
Total Non-Current Assets3.903.173.693.693.642.302.532.73
Total Assets19.0334.7227.8927.895.538.1314.013.28
Current Liabilities
Accounts Payable4.365.573.783.786.784.463.390.00
Short-Term Debt0.430.330.65-16.676.163.614.61
Current Portion of Long-Term Debt----15.416.163.61-
Accrued Liabilities1.441.00-2.125.006.967.22-
Deferred Revenue0.000.000.00-0.174.500.000.00
Other Current Liabilities1.441.002.12-8.026.969.6810.12
Total Current Liabilities6.236.906.556.5531.6322.4814.4914.73
Non-Current Liabilities
Long-Term Debt1.261.541.871.879.6918.0221.6913.37
Other Non-Current Liabilities0.000.000.00-0.000.000.000.00
Total Non-Current Liabilities1.261.541.871.879.6918.7522.1713.37
Total Liabilities7.488.448.428.4241.3141.2436.6628.09
Stockholders' Equity
Common Stock0.040.040.030.030.010.010.030.02
Retained Earnings-283.54-251.39-221.52-221.52-189.78-184.58-168.23-154.59
Accumulated Other Comprehensive Income0.010.060.010.010.000.000.000.00
Treasury Stock0.430.43-0.430.430.43--
Additional Paid-in Capital295.47278.00240.96241.39153.97151.43145.52129.73
Shares Outstanding38.1434.73-26.7923.5723.57--
Total Stockholders' Equity11.5426.2719.4719.47-35.78-33.11-22.66-24.81
Total Liabilities & Equity19.0334.7227.8927.895.538.1314.013.28

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Genelux Balance Sheet

How much debt does Genelux have?

Genelux had total debt of $1.69M as of Dec 31, 2025, against $14.60M in cash and short-term investments. Its debt-to-equity ratio was 0.15. Total debt was $1.87M a year earlier.

What are Genelux's total assets?

Genelux reported total assets of $19.03M as of Dec 31, 2025, down 45.2% from $34.72M a year earlier. Total liabilities were $7.48M.

What is Genelux's shareholders' equity?

Genelux's shareholders' equity was $11.54M as of Dec 31, 2025, or about $0.30 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition